Giuseppina Uccello

434 total citations
12 papers, 125 citations indexed

About

Giuseppina Uccello is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Giuseppina Uccello has authored 12 papers receiving a total of 125 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 5 papers in Genetics and 5 papers in Oncology. Recurrent topics in Giuseppina Uccello's work include Multiple Myeloma Research and Treatments (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Peptidase Inhibition and Analysis (3 papers). Giuseppina Uccello is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Peptidase Inhibition and Analysis (3 papers). Giuseppina Uccello collaborates with scholars based in Italy and Montenegro. Giuseppina Uccello's co-authors include Massimo Gentile, Annamaria Petrungaro, Fortunato Morabito, Ernesto Vigna, Anna Grazia Recchia, Laura De Stefano, Sabrina Bossio, Massimo Martino, Francesco Di Raimondo and Iolanda Donatella Vincelli and has published in prestigious journals such as Blood, Annals of Oncology and Frontiers in Oncology.

In The Last Decade

Giuseppina Uccello

10 papers receiving 124 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Giuseppina Uccello Italy 8 67 65 42 37 31 12 125
Immacolata Attolico Italy 6 82 1.2× 27 0.4× 44 1.0× 47 1.3× 29 0.9× 17 146
Ory Rouvio Israel 7 71 1.1× 76 1.2× 51 1.2× 38 1.0× 20 0.6× 19 126
Lukas M. Braun Germany 9 67 1.0× 63 1.0× 53 1.3× 28 0.8× 43 1.4× 11 172
Hideharu Muto Japan 5 57 0.9× 70 1.1× 46 1.1× 24 0.6× 51 1.6× 16 160
Fabienne Lucas United States 8 77 1.1× 68 1.0× 51 1.2× 68 1.8× 60 1.9× 22 192
Hong L. Tiv United States 5 50 0.7× 68 1.0× 40 1.0× 22 0.6× 22 0.7× 7 130
Zunmin Zhu China 8 60 0.9× 94 1.4× 48 1.1× 41 1.1× 48 1.5× 39 212
Camila Peña Chile 6 54 0.8× 43 0.7× 36 0.9× 26 0.7× 12 0.4× 43 111
Kalyan Nadiminti United States 6 68 1.0× 65 1.0× 24 0.6× 18 0.5× 19 0.6× 24 115
Hein Than Singapore 7 59 0.9× 74 1.1× 24 0.6× 38 1.0× 15 0.5× 22 147

Countries citing papers authored by Giuseppina Uccello

Since Specialization
Citations

This map shows the geographic impact of Giuseppina Uccello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppina Uccello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppina Uccello more than expected).

Fields of papers citing papers by Giuseppina Uccello

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuseppina Uccello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppina Uccello. The network helps show where Giuseppina Uccello may publish in the future.

Co-authorship network of co-authors of Giuseppina Uccello

This figure shows the co-authorship network connecting the top 25 collaborators of Giuseppina Uccello. A scholar is included among the top collaborators of Giuseppina Uccello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuseppina Uccello. Giuseppina Uccello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Fabro, Vittorio Del, Giulia Sapuppo, Giuseppina Uccello, et al.. (2023). P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN. HemaSphere. 7(S2). 21–22.
3.
Markovic, Uroš, Alessandra Romano, Vittorio Del Fabro, et al.. (2021). Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Frontiers in Oncology. 11. 624405–624405. 7 indexed citations
4.
Gentile, Massimo, Annamaria Petrungaro, Giuseppina Uccello, et al.. (2017). Venetoclax for the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs. 26(11). 1307–1316. 42 indexed citations
5.
6.
Mauro, Francesca Romana, Fortunato Morabito, Iolanda Donatella Vincelli, et al.. (2017). Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leukemia Research. 57. 65–71. 19 indexed citations
7.
Uccello, Giuseppina, Annamaria Petrungaro, Carla Mazzone, et al.. (2016). Pomalidomide in multiple myeloma. Expert Opinion on Pharmacotherapy. 18(2). 133–137. 11 indexed citations
8.
Gentile, Massimo, Valeria Magarotto, Massimo Offidani, et al.. (2016). Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. American Journal of Hematology. 92(3). 244–250. 15 indexed citations
9.
Romano, Alessandra, et al.. (2013). Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients. Current Cancer Therapy Reviews. 9(1). 1–7. 1 indexed citations
10.
Romano, Alessandra, et al.. (2013). Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients. Current Cancer Therapy Reviews. 9(1). 1–7. 1 indexed citations
11.
Romano, Alessandra, Annalisa Chiarenza, Ugo Consoli, et al.. (2012). Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Annals of Oncology. 24(4). 1038–1044. 11 indexed citations
12.
Palumbo, Antonio, Sara Galimberti, Oreste Villani, et al.. (2012). Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. Blood. 120(21). 730–730. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Immacolata Attolico Breakdown of academic impact, for papers by Ory Rouvio Breakdown of academic impact, for papers by Lukas M. Braun Breakdown of academic impact, for papers by Hideharu Muto Breakdown of academic impact, for papers by Fabienne Lucas Breakdown of academic impact, for papers by Hong L. Tiv Breakdown of academic impact, for papers by Zunmin Zhu Breakdown of academic impact, for papers by Camila Peña Breakdown of academic impact, for papers by Kalyan Nadiminti Breakdown of academic impact, for papers by Hein Than
Rankless by CCL
2026